#1 Clinical Trials Search in Europe

Dornase Alfa

Dornase Alfa, also known as Pulmozyme, is a recombinant human DNase enzyme that has been widely used in the treatment of cystic fibrosis. Recent clinical trials are exploring its potential benefits in various other respiratory conditions, including COVID-19, acute respiratory distress syndrome (ARDS), and ventilator-associated infections. This article summarizes the ongoing research and potential applications of Dornase Alfa beyond its traditional use.

Table of Contents

What is Dornase Alfa?

Dornase alfa, also known by its brand name Pulmozyme, is a medication used to help improve lung function in certain respiratory conditions. It is a highly purified solution of recombinant human deoxyribonuclease I (rhDNase), which is an enzyme that our body naturally produces[1]. This medication is designed to be inhaled directly into the lungs using a nebulizer, which is a device that turns liquid medicine into a fine mist that can be breathed in[2].

How Does It Work?

Dornase alfa works by breaking down a type of DNA found in mucus. In some respiratory conditions, there can be an excessive amount of DNA in the mucus, making it thick and sticky. This thick mucus can clog airways and make breathing difficult. Dornase alfa helps to thin this mucus by breaking down the DNA, making it easier to clear from the lungs[3]. This process can help improve lung function and make breathing easier for patients with certain conditions.

Conditions Treated with Dornase Alfa

Dornase alfa is primarily used to treat the following conditions:

  • Cystic Fibrosis (CF): This is the main condition for which dornase alfa is approved. CF is a genetic disorder that affects the lungs and other organs, causing thick, sticky mucus to build up[4].
  • COVID-19 Related Respiratory Issues: Research is being conducted to see if dornase alfa can help patients with severe COVID-19 who are on mechanical ventilation[5].
  • Acute Respiratory Distress Syndrome (ARDS): Studies are exploring the use of dornase alfa in patients with ARDS, a severe lung condition that can occur with COVID-19 and other illnesses[3].
  • Sjögren’s Syndrome: Research is being done to see if dornase alfa can help with chronic cough associated with Sjögren’s syndrome, an autoimmune disorder that affects mucus-producing glands[1].

How is Dornase Alfa Administered?

Dornase alfa is typically administered through inhalation using a nebulizer. The usual dose is 2.5 mg (2.5 ml of solution) inhaled once or twice daily[2]. The medication is breathed in through a mouthpiece or mask connected to the nebulizer. The process usually takes about 10-15 minutes per dose. It’s important to follow your doctor’s instructions carefully when using this medication.

Ongoing Research and Potential New Uses

Scientists are continually studying dornase alfa to understand its potential benefits in other conditions. Some areas of ongoing research include:

  • Stroke Treatment: Researchers are investigating whether dornase alfa could help improve outcomes in patients with certain types of stroke[6].
  • Pleural Effusions: Studies are looking at whether dornase alfa, when combined with other medications, could help treat fluid buildup around the lungs[7].
  • Ventilator-Associated Infections: Research is being conducted to see if dornase alfa could help prevent or treat lung infections in patients on mechanical ventilation, including premature infants[8].

Side Effects and Safety

Dornase alfa is generally well-tolerated, but like all medications, it can have side effects. Common side effects may include:

  • Voice changes or hoarseness
  • Sore throat
  • Chest pain
  • Rash

In most clinical trials, the safety of dornase alfa is closely monitored. For example, in a study of its use in COVID-19 patients, researchers specifically looked at any adverse reactions to ensure the medication’s safety[1].

It’s important to discuss any concerns or potential side effects with your healthcare provider. They can provide personalized advice based on your specific health situation and help monitor for any adverse effects.

Aspect Details
Traditional Use Treatment of cystic fibrosis to improve mucus clearance
Mechanism of Action Breaks down DNA in mucus and neutrophil extracellular traps (NETs)
New Potential Applications COVID-19, ARDS, ventilator-associated infections, ischemic stroke, Sjogren’s syndrome-associated cough
Administration Method Nebulization, often 2.5 mg once or twice daily
Primary Outcomes Studied Improved lung function, reduced inflammation, shortened ventilation time, better oxygenation (PaO2/FiO2 ratio)
Safety Profile Generally well-tolerated; specific side effects in new applications under investigation
Current Stage Various Phase II and IV clinical trials ongoing

FAQ

  • What is Dornase Alfa? Dornase Alfa is a recombinant human DNase enzyme that breaks down DNA in mucus, making it thinner and easier to clear from the airways. It is commonly used in the treatment of cystic fibrosis.
  • What conditions are being studied for potential Dornase Alfa treatment? Clinical trials are exploring the use of Dornase Alfa in conditions such as COVID-19, acute respiratory distress syndrome (ARDS), ventilator-associated infections, ischemic stroke, and Sjogren's syndrome-associated cough.
  • How is Dornase Alfa administered in clinical trials? In most trials, Dornase Alfa is administered through nebulization, either directly into the airways or through ventilator circuits. The typical dose is 2.5 mg, usually given once or twice daily.
  • What are the potential benefits of Dornase Alfa in these new applications? Researchers hope that Dornase Alfa may improve lung function, reduce inflammation, shorten ventilation time, and improve overall outcomes in various respiratory conditions by breaking down thick mucus and neutrophil extracellular traps (NETs).
  • Are there any known side effects of Dornase Alfa? Dornase Alfa is generally well-tolerated. However, as with any medication, side effects can occur. In cystic fibrosis patients, common side effects include voice alterations, sore throat, and rash. Specific side effects in new applications are being studied in ongoing trials.

Ongoing Clinical Trials on Dornase Alfa

  • Study on the Effects of Dornase Alfa for Patients with Subarachnoid Hemorrhage to Improve Independence After 6 Months

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Dornase Alfa and Placebo to Reduce ARDS in Ventilated Trauma Patients in ICU

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Dornase Alfa and Alteplase with Surgery for Treating Pleural Empyema in Patients

    Recruiting

    3 1 1 1
    Investigated drugs:
    Denmark

  • Early Saline Pleural Irrigation for Patients with Complicated Pleural Infections

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of dornase alfa and cisplatin treatment for patients with refractory germ cell cancer

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    Slovakia

  • Study on Reducing Inflammation in Acute Ischemic Stroke Patients Using Dornase Alfa and Sodium Chloride

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Effectiveness of Dornase Alfa for Improving Blood Flow in Patients with Ischemic Stroke Eligible for Thrombectomy

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France

Glossary

  • Dornase Alfa: A recombinant human DNase enzyme that breaks down DNA in mucus, making it thinner and easier to clear from the airways.
  • Neutrophil Extracellular Traps (NETs): Web-like structures released by neutrophils (a type of white blood cell) that contain DNA and proteins, which can contribute to inflammation and thickening of mucus.
  • Acute Respiratory Distress Syndrome (ARDS): A severe lung condition characterized by rapid onset of widespread inflammation in the lungs, leading to difficulty breathing and low blood oxygen levels.
  • Nebulization: The process of converting a liquid medication into a fine mist that can be inhaled into the lungs.
  • Endotracheal: Referring to a procedure or device that is inserted through the mouth or nose and into the trachea (windpipe).
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function that represents the amount of air a person can forcefully exhale in one second.
  • PaO2/FiO2 ratio: A measure of the oxygen level in the blood compared to the amount of oxygen being delivered, used to assess the severity of respiratory problems.
  • Mucolytic: A substance that helps break down and thin mucus, making it easier to clear from the airways.

References

  1. https://clinicaltrials.gov/study/NCT01357447
  2. https://clinicaltrials.gov/study/NCT01712334
  3. https://clinicaltrials.gov/study/NCT04402970
  4. https://clinicaltrials.gov/study/NCT00680316
  5. https://clinicaltrials.gov/study/NCT04387786
  6. https://clinicaltrials.gov/study/NCT05203224
  7. https://clinicaltrials.gov/study/NCT02135588
  8. https://clinicaltrials.gov/study/NCT01356147